Read by QxMD icon Read

Alzheimer's & Dementia: the Journal of the Alzheimer's Association

David S Knopman, Rebecca F Gottesman, A Richey Sharrett, Amanda L Tapia, Sonia DavisThomas, B Gwen Windham, Laura Coker, Andrea L C Schneider, Alvaro Alonso, Josef Coresh, Marilyn S Albert, Thomas H Mosley
INTRODUCTION: The interplay between midlife vascular risk factors and midlife cognitive function with later life mild cognitive impairment (MCI) and dementia (DEM) is not well understood. METHODS: In the Atherosclerosis Risk in Communities Study, cardiovascular risk factors and cognition were assessed in midlife, ages 45-64 years. In 2011-2013, 20-25 years later, all consenting Atherosclerosis Risk in Communities participants underwent a cognitive and neurological evaluation and were given adjudicated diagnoses of cognitively normal, MCI, or DEM...
May 12, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Michael W Weiner, Rachel Nosheny, Monica Camacho, Diana Truran-Sacrey, R Scott Mackin, Derek Flenniken, Aaron Ulbricht, Philip Insel, Shannon Finley, Juliet Fockler, Dallas Veitch
INTRODUCTION: Recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies and clinical trials limit the development of new treatments. Widespread Internet use allows data capture from participants in an unsupervised setting. The Brain Health Registry, a website and online registry, collects data from participants and their study partners. METHODS: The Brain Health Registry obtains self and study partner report questionnaires and neuropsychological data, including the Cogstate Brief Battery, Lumos Labs Neurocognitive Performance Test, and MemTrax Memory Test...
May 8, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Takeshi Iwatsubo, Atsushi Iwata, Kazushi Suzuki, Ryoko Ihara, Hiroyuki Arai, Kenji Ishii, Michio Senda, Kengo Ito, Takeshi Ikeuchi, Ryozo Kuwano, Hiroshi Matsuda, Chung-Kai Sun, Laurel A Beckett, Ronald C Petersen, Michael W Weiner, Paul S Aisen, Michael C Donohue
INTRODUCTION: We conducted Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) and compared the basic characteristics and progression profiles with those of ADNI in North America. METHODS: A total of 537 Japanese subjects with normal cognition, late amnestic mild cognitive impairment (LMCI), or mild Alzheimer's disease (AD) were enrolled using the same criteria as ADNI. Rates of changes in representative cognitive or functional measures were compared for amyloid positron emission tomography- or cerebrospinal fluid amyloid β(1-42)-positive LMCI and mild AD between J-ADNI and ADNI...
May 8, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Peng Li, Lei Yu, Andrew S P Lim, Aron S Buchman, Frank A J L Scheer, Steven A Shea, Julie A Schneider, David A Bennett, Kun Hu
INTRODUCTION: Healthy physiological systems exhibit fractal regulation (FR), generating similar fluctuation patterns in physiological outputs across different time scales. FR in motor activity is degraded in dementia, and the degradation correlates to cognitive decline. We tested whether degraded FR predicts Alzheimer's disease dementia. METHODS: FR in motor activity was assessed in 1097 nondemented older adults at baseline. Cognition was assessed annually for up to 11 years...
May 4, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Daniele Altomare, Clarissa Ferrari, Cristina Festari, Ugo Paolo Guerra, Cristina Muscio, Alessandro Padovani, Giovanni B Frisoni, Marina Boccardi
INTRODUCTION: We test the hypothesis that amyloid-PET prescriptions, considered appropriate based on the Amyloid Imaging Taskforce (AIT) criteria, lead to greater clinical utility than AIT-inappropriate prescriptions. METHODS: We compared the clinical utility between patients who underwent amyloid-PET appropriately or inappropriately and among the subgroups of patients defined by the AIT criteria. Finally, we performed logistic regressions to identify variables associated with clinical utility...
April 18, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Ralph Buchert, Catharina Lange, Per Suppa, Ivayla Apostolova, Lothar Spies, Stefan Teipel, Bruno Dubois, Harald Hampel, Michel J Grothe
No abstract text is available yet for this article.
April 18, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Mustapha Bouhrara, David A Reiter, Christopher M Bergeron, Linda M Zukley, Luigi Ferrucci, Susan M Resnick, Richard G Spencer
INTRODUCTION: We investigated brain demyelination in aging, mild cognitive impairment (MCI), and dementia using magnetic resonance imaging of myelin. METHODS: Brains of young and old controls and old subjects with MCI, Alzheimer's disease, or vascular dementia were scanned using our recently developed myelin water fraction (MWF) mapping technique, which provides greatly improved accuracy over previous comparable methods. Maps of MWF, a direct and specific myelin measure, and relaxation times and magnetization transfer ratio, indirect and nonspecific measures, were constructed...
April 18, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Hugh C Hendrie, Mengjie Zheng, Kathleen A Lane, Roberta Ambuehl, Christianna Purnell, Shanshan Li, Frederick W Unverzagt, Michael D Murray, Ashok Balasubramanyam, Chris M Callahan, Sujuan Gao
INTRODUCTION: Changes in glucose levels may represent a powerful metabolic indicator of dementia in African-Americans with diabetes. It is unclear whether these changes also occur in Caucasians. METHODS: A secondary data analysis using electronic medical records from 5228 African-Americans and Caucasians aged ≥65 years was carried out. Mixed effects models with repeated serum glucose measurements were used to compare changes in glucose levels between African-Americans and Caucasian patients with and without incident dementia...
April 17, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Michael S Unger, Julia Marschallinger, Julia Kaindl, Barbara Klein, Mary Johnson, Ahmad A Khundakar, Stefan Roßner, Michael T Heneka, Sebastien Couillard-Despres, Ed Rockenstein, Eliezer Masliah, Johannes Attems, Ludwig Aigner
One characteristic of Alzheimer's disease is the formation of amyloid-β plaques, which are typically linked to neuroinflammation and surrounded by inflammatory cells such as microglia and infiltrating immune cells. Here, we describe nonneurogenic doublecortin (DCX) positive cells, DCX being generally used as a marker for young immature neurons, at sites of amyloid-β plaques in various transgenic amyloid mouse models and in human brains with plaque pathology. The plaque-associated DCX+ cells were not of neurogenic identity, instead most of them showed coexpression with markers for microglia (Iba1) and for phagocytosis (CD68 and TREM2)...
April 6, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Edwin C K Tan, Kristina Johnell, Sara Garcia-Ptacek, Miriam L Haaksma, Johan Fastbom, J Simon Bell, Maria Eriksdotter
INTRODUCTION: The aim of this study was to investigate the association between acetylcholinesterase inhibitor (AChEI) use and risk of ischemic stroke and death in people with dementia. METHODS: A cohort study of 44,288 people with dementia registered in the Swedish Dementia Registry from 2007 to 2014. Propensity score-matched competing risk regression models were used to compute hazard ratios and 95% confidence intervals for the association between time-dependent AChEI use and risk of stroke and death...
April 5, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Andrew Sommerlad, Gayan Perera, Archana Singh-Manoux, Glyn Lewis, Robert Stewart, Gill Livingston
INTRODUCTION: Recognizing dementia in general hospitals allows for tailored care. We aimed to assess hospital dementia diagnosis accuracy, changes over time, and predictors of correct identification. METHOD: Retrospective cohort study of people over 65 years, using data from a large mental health care database as gold standard, linked to 2008-2016 English hospital data. RESULTS: In 21,387 people who had 138,455 admissions, we found sensitivity and specificity of dementia recording, respectively, to be 78...
April 5, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Michelle M Mielke, Clinton E Hagen, Jing Xu, Xiyun Chai, Prashanthi Vemuri, Val J Lowe, David C Airey, David S Knopman, Rosebud O Roberts, Mary M Machulda, Clifford R Jack, Ronald C Petersen, Jeffrey L Dage
INTRODUCTION: We examined and compared plasma phospho-tau181 (pTau181) and total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid β (Aβ) positron emission tomography (PET), tau PET, and cortical thickness; and (3) as a screening tool for elevated brain Aβ. METHODS: Participants included 172 cognitively unimpaired, 57 mild cognitively impaired, and 40 AD dementia patients with concurrent Aβ PET (Pittsburgh compound B), tau PET (AV1451), magnetic resonance imaging, plasma total tau, and pTau181...
April 4, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Tim Wilkinson, Amanda Ly, Christian Schnier, Kristiina Rannikmäe, Kathryn Bush, Carol Brayne, Terence J Quinn, Cathie L M Sudlow
INTRODUCTION: Prospective, population-based studies can be rich resources for dementia research. Follow-up in many such studies is through linkage to routinely collected, coded health-care data sets. We evaluated the accuracy of these data sets for dementia case identification. METHODS: We systematically reviewed the literature for studies comparing dementia coding in routinely collected data sets to any expert-led reference standard. We recorded study characteristics and two accuracy measures-positive predictive value (PPV) and sensitivity...
April 2, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Priya Palta, Honglei Chen, Jennifer A Deal, A Richey Sharrett, Alden Gross, David Knopman, Michael Griswold, Gerardo Heiss, Thomas H Mosley
INTRODUCTION: We tested the hypothesis that poor sense of smell is associated with lower cognitive function and higher mild cognitive impairment (MCI) prevalence. METHODS: Olfaction, measured by the Sniffin' Sticks test, was categorized as olfactory impairment (OI) (score ≤6) or no OI (score >6). MCI was adjudicated based on review of a neuropsychological examination. Linear regression estimated the mean difference in cognitive factor scores, and log-binomial regression quantified MCI prevalence among participants with versus without OI...
March 29, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Jennifer L Whitwell, Jonathan Graff-Radford, Nirubol Tosakulwong, Stephen D Weigand, Mary Machulda, Matthew L Senjem, Anthony J Spychalla, Prashanthi Vemuri, David T Jones, Daniel A Drubach, David S Knopman, Bradley F Boeve, Nilüfer Ertekin-Taner, Ronald C Petersen, Val J Lowe, Clifford R Jack, Keith A Josephs
INTRODUCTION: Neuroimaging modalities can measure different aspects of the disease process in Alzheimer's disease, although the relationship between these modalities is unclear. METHODS: We assessed subject-level regional correlations between tau on [18 F]AV-1451 positron emission tomography (PET), β amyloid on Pittsburgh compound B PET, hypometabolism on [18 F] fluorodeoxyglucose PET, and cortical thickness on magnetic resonance imaging in 96 participants with typical and atypical Alzheimer's disease presentations...
March 29, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Sirwan K L Darweesh, Frank J Wolters, M Arfan Ikram, Frank de Wolf, Daniel Bos, Albert Hofman
INTRODUCTION: Inflammatory markers are often elevated in patients with dementia, including Alzheimer's disease (AD). However, it remains unclear whether inflammatory markers are associated with the risk of developing dementia. METHODS: We searched PubMed, Embase, and Cochrane library for prospective population-based studies reporting associations between inflammatory markers and all-cause dementia or AD. We used random effects meta-analyses to obtain pooled hazard ratios (HRs) and 95% confidence intervals of inflammatory markers (highest vs...
March 29, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Lisa Vermunt, Colin D Veal, Lea Ter Meulen, Charalambos Chrysostomou, Wiesje van der Flier, Giovanni B Frisoni, Idris Guessous, Miia Kivipelto, Moira Marizzoni, Pablo Martinez-Lage, José Luis Molinuevo, David Porteous, Karen Ritchie, Philip Scheltens, Pierre-Jean Ousset, Craig W Ritchie, Gerald Luscan, Anthony J Brookes, Pieter Jelle Visser
INTRODUCTION: It is a challenge to find participants for Alzheimer's disease (AD) prevention trials within a short period of time. The European Prevention of Alzheimer's Dementia Registry (EPAD) aims to facilitate recruitment by preselecting subjects from ongoing cohort studies. This article introduces this novel approach. METHODS: A virtual registry, with access to risk factors and biomarkers for AD through minimal data sets of ongoing cohort studies, was set up...
March 28, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Min Shi, Lu Tang, Jon B Toledo, Carmen Ginghina, Hua Wang, Patrick Aro, Poul H Jensen, Daniel Weintraub, Alice S Chen-Plotkin, David J Irwin, Murray Grossman, Leo McCluskey, Lauren B Elman, David A Wolk, Edward B Lee, Leslie M Shaw, John Q Trojanowski, Jing Zhang
INTRODUCTION: The ability of Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid β peptide 1-42, total tau, and phosphorylated tau) to discriminate AD from related disorders is limited. Biomarkers for other concomitant pathologies (e.g., CSF α-synuclein [α-syn] for Lewy body pathology) may be needed to further improve the differential diagnosis. METHODS: CSF total α-syn, phosphorylated α-syn at Ser129, and AD CSF biomarkers were evaluated with Luminex immunoassays in 367 participants, followed by validation in 74 different neuropathologically confirmed cases...
March 28, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Niklas Mattsson, Colin Groot, Willemijn J Jansen, Susan M Landau, Victor L Villemagne, Sebastiaan Engelborghs, Mark M Mintun, Alberto Lleo, José Luis Molinuevo, William J Jagust, Giovanni B Frisoni, Adrian Ivanoiu, Gaël Chételat, Catarina Resende de Oliveira, Karen M Rodrigue, Johannes Kornhuber, Anders Wallin, Aleksandra Klimkowicz-Mrowiec, Ramesh Kandimella, Julius Popp, Pauline P Aalten, Dag Aarsland, Daniel Alcolea, Ina S Almdahl, Inês Baldeiras, Mark A van Buchem, Enrica Cavedo, Kewei Chen, Ann D Cohen, Stefan Förster, Juan Fortea, Kristian S Frederiksen, Yvonne Freund-Levi, Kiran Dip Gill, Olymbia Gkatzima, Timo Grimmer, Harald Hampel, Sanna-Kaisa Herukka, Peter Johannsen, Koen van Laere, Mony J de Leon, Wolfgang Maier, Jan Marcusson, Olga Meulenbroek, Hanne M Møllergård, John C Morris, Barbara Mroczko, Arto Nordlund, Sudesh Prabhakar, Oliver Peters, Lorena Rami, Eloy Rodríguez-Rodríguez, Catherine M Roe, Eckart Rüther, Isabel Santana, Johannes Schröder, Sang W Seo, Hilkka Soininen, Luiza Spiru, Erik Stomrud, Hanne Struyfs, Charlotte E Teunissen, Frans R J Verhey, Stephanie J B Vos, Linda J C van Waalwijk van Doorn, Gunhild Waldemar, Åsa K Wallin, Jens Wiltfang, Rik Vandenberghe, David J Brooks, Tormod Fladby, Christopher C Rowe, Alexander Drzezga, Marcel M Verbeek, Marie Sarazin, David A Wolk, Adam S Fleisher, William E Klunk, Duk L Na, Pascual Sánchez-Juan, Dong Young Lee, Agneta Nordberg, Magda Tsolaki, Vincent Camus, Juha O Rinne, Anne M Fagan, Henrik Zetterberg, Kaj Blennow, Gil D Rabinovici, Oskar Hansson, Bart N M van Berckel, Wiesje M van der Flier, Philip Scheltens, Pieter Jelle Visser, Rik Ossenkoppele
INTRODUCTION: Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology. METHODS: We included 3451 Aβ+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location...
March 28, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Raffaele Cacciaglia, José Luis Molinuevo, Carles Falcón, Anna Brugulat-Serrat, Gonzalo Sánchez-Benavides, Nina Gramunt, Manel Esteller, Sebastián Morán, Carolina Minguillón, Karine Fauria, Juan Domingo Gispert
INTRODUCTION: Apolipoprotein E (APOE)-ε4 is the major genetic risk factor for Alzheimer's disease. However, the dose-dependent impact of this allele on brain morphology of healthy individuals remains unclear. METHODS: We analyzed gray matter volumes (GMvs) in a sample of 533 healthy middle-aged individuals with a substantial representation of ε4-carriers (207 heterozygotes and 65 homozygotes). RESULTS: We found APOE-ε4 additive GMv reductions in the right hippocampus, caudate, precentral gyrus, and cerebellar crus...
March 27, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"